We have developed FANA-modified antisenses oligonucleotides specifically targeting PDE isotypes 4B, 4D and 7A, as a potential new inhaled drug for the treatment of COPD. The gene discussed is ALDH7A1; the disease is chronic obstructive pulmonary disease.